Clinical Trial Search

Primary: Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First. — 1.3; 3.6 cm2

Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change

Primary: The Primary Outcome Measure Will be Subjects Ethanol Consumption Over the Course of the Drug Treatment Period as Assessed by the Timeline Followback Method — -4.9…

Primary: Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion — 68.4; 62.1; 61.3 percentage of patients — p=0.039

Primary: Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet. — 149; 33; 38 participants — p=<0.0001

Primary: Uncorrected and Best Corrected Visual Acuities (Near and Distance) — 0.02; 0.01; 0.00; -0.03 logMAR

Primary: Percent of Participants Classified as Responders — 76.7; 80.0 percent of participants — p=<0.0001

Primary: Median Change in Total Propionibacterium Acne (P.Acne) Counts — -1.26; -0.08; -1.58; -0.67 P. acne counts

Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05

Primary: Percentage of Participants With at Least 1 Solicited Injection Site and Systemic Reactions Post-Vaccination — 89; 88; 2; 29 Percentage of Participants

Primary: Percent rhGH Injections Missed During the Treatment Period (Based on the Easypod™ Injection Log) — 20; 19.46; 20 Percent of injections missed — p=0.908

Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). — 118.6; 14.8; 142.8; 24.2 mIU/mL

Primary: Corneal Sensitivity — 26.9; 25.5 percent CO2

Primary: Occurrence of Contrast-induced Nephropathy — 1; 8 participants

Primary: Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months — 46; 150; 11 participants